Cannabis as a Treatment for Epilepsy. 7 studies

Cannabis as a Treatment for Epilepsy

Epilepsy is the third most common chronic brain disorder, and is characterized by an enduring predisposition to generate seizures. Epilepsy is affecting about 3 million Americans and 65 million people worldwide.

About 80% of individuals diagnosed with epilepsy are from low-to-middle income countries.  

Despite progress in pharmacological and surgical treatments of epilepsy, relatively little is known about the processes leading to the generation of individual seizures, and about the mechanisms whereby a healthy brain is rendered epileptic. 

Epilepsy can be caused by congenital abnormalities, genetic predisposition, brain infections, brain cancer and tumors, and neurological disorders like stroke or injuries to the brain.

Medications can control epilepsy symptoms, but they may have serious long-term complications. Researchers looking for safer, more effective alternative epilepsy treatments have discovered that cannabinoids, particularly CBD, may be the answer.

The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials 

https://pubmed.ncbi.nlm.nih.gov/31916540/

The proposed mechanisms of action of CBD in epilepsy. 

https://pubmed.ncbi.nlm.nih.gov/32053110/ 

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

https://pubmed.ncbi.nlm.nih.gov/24854329/

Expert advice for prescribing cannabis medicines for patients with epilepsy—drawn from the Australian clinical experience

https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.15262

Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy

https://www.epilepsybehavior.com/article/S1525-5050(21)00466-2/fulltext

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514832/ 

Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps

https://www.frontiersin.org/articles/10.3389/fneur.2020.531939/full